Lumbar Degenerative Disc Disease Market by Treatment, Route of Administration, End-Users

Description

List of Tables

[196 Pages Report] The Lumbar Degenerative Disc Disease Market size was estimated at USD 744.58 million in 2023 and expected to reach USD 796.33 million in 2024, at a CAGR 7.15% to reach USD 1,207.76 million by 2030.

Lumbar degenerative disc disease (LDDD) is a condition impacting the lower spine that involves the loss of fluid, flexibility, and shock absorption capabilities in the intervertebral discs over time. These changes can lead to the discs' inability to cushion the lumbar vertebrae effectively, resulting in pain, instability, and reduced mobility. LDDD is a natural part of aging and can be exacerbated by factors such as genetics, lifestyle, and injury. With the rising number of elderly individuals worldwide, LDDD becomes more susceptible to degenerative conditions, leading to an increased need for treatments and therapies specifically targeting LDDD. Increased awareness and education about LDDD among both patients and healthcare providers have led to higher diagnosis rates and a more proactive approach to management. This greater understanding of the disease encourages individuals to seek treatment sooner, thereby expanding the patient pool for LDDD therapies. Expansion in healthcare expenditure and improvements in insurance coverage for degenerative diseases are also expanding the accessibility of lumbar degenerative disc disease therapies. The high cost associated with advanced treatments and surgeries with LDDD hampers the market growth. The development of innovative diagnostic and treatment technologies has significantly contributed to the growth of the LDDD market. Improved imaging techniques, such as MRI and CT scans, allow for early and precise diagnosis, while advancements in surgical procedures and non-invasive treatments offer more effective management options for patients.

KEY MARKET STATISTICS
Base Year [2023]	USD 744.58 million
Estimated Year [2024]	USD 796.33 million
Forecast Year [2030]	USD 1,207.76 million
CAGR (%)	7.15%

Treatment: Rising usage of epidural steroid injections (ESIs) for management of lumbar degenerative disc disease

Epidural steroid injections (ESIs) are a common treatment option for lumbar degenerative disc disease, aimed at reducing inflammation and relieving pain. This procedure involves the direct delivery of corticosteroids and an anesthetic into the epidural space surrounding the spinal cord, offering temporary relief that can last from weeks to years, depending on individual patient response. Acetaminophen is recommended for pain relief. It acts primarily by reducing the perception of pain, with a significantly lower risk of causing GI distress or cardiovascular issues. Nevertheless, caution regarding liver toxicity with high doses or chronic use is advised. Nonsteroidal anti-inflammatory drugs (NSAIDs) help to reduce inflammation and pain. While effective, they should be used judiciously due to potential side effects, including gastrointestinal (GI) complications or increased cardiovascular risk with long-term use. Oral corticosteroids can be prescribed for acute episodes of severe pain due to their powerful anti-inflammatory properties. However, due to the potential for side effects, their use is typically limited to short durations. Muscle relaxants are prescribed to alleviate muscle spasms, which are a common symptomatic complication of lumbar degenerative disc disease. While effective for short-term relief, care must be taken due to potential sedation effects and dependency risks. For severe pain that does not respond to other therapies, narcotics or opioids may be considered for short-term management. Due to their high potential for dependency and overdose, opioids are strictly regulated and considered a last resort, emphasizing the importance of monitoring and cautious use.

End-Users: Increasing need for lumbar degenerative disc disease treatment for diagnosing, treating, and managing patients

Academic research centers are pivotal in lumbar degenerative disc disease, primarily focused on advancing the understanding of LDDD pathology, treatment efficacy, and outcomes. These centers are crucial for conducting early-stage research, including preclinical and clinical studies, that inform the development and refinement of therapeutic strategies. They are hubs for innovation, often partnering with industry stakeholders to translate foundational research into practical treatments. Their work contributes to academic knowledge and directly impacts clinical practices and patient care strategies globally. Hospitals & clinics represent a critical segment of the end-user market for LDDD treatments. They are the primary facilities for diagnosing, treating, and managing patients with LDDD, offering non-surgical and surgical treatment options. These institutions play a key role in directly applying new research findings and innovative therapies to patient care. Their frontline experience with patient outcomes and treatment efficacy provides valuable real-world data that can feed back into the research and development cycle, helping to refine and improve LDDD management strategies. Specialty clinics provide targeted and highly specialized patient care, offering a range of treatments from conservative management to advanced surgical interventions. They are often at the forefront of implementing new technologies and minimally invasive procedures to improve patient recovery times and outcomes. Specialty clinics also often participate in clinical trials, contributing to developing new LDDD treatments and therapies. Their focused expertise makes them valuable centers for patient education and advocacy, as well as research and treatment innovation in the realm of spine health.

Regional Insights

The Americas represents a significant market for the lumbar degenerative disc disease market, primarily due to the higher incidence rates of spinal disorders, a well-established healthcare infrastructure, and leading medical device companies. Additionally, the aging population in the Americas further escalates the need for treatment options, making it a lucrative market for lumbar degenerative disc disease therapies and surgeries. Asia-Pacific region is the growing market for lumbar degenerative disc disease treatment, driven by rapidly developing healthcare infrastructure, increasing disposable incomes, and a rising prevalence of lifestyle-induced spinal conditions. Countries including China and India are at the forefront due to their large population base, increasing elderly population, and growing awareness of treatment options. Moreover, governments in these countries are increasingly investing in healthcare, further fueling market growth. The EMEA region presents a diverse market scenario. Europe, being more developed, shows a higher need for advanced treatments driven by an increase in the aging population, high healthcare expenditure, and established healthcare systems. On the other hand, the Middle East and Africa are emerging markets with growing potential, mainly due to improving healthcare infrastructure, economic development, and a burgeoning middle class. However, the market growth in the African region is somewhat hampered by the lack of awareness and limited access to healthcare facilities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lumbar Degenerative Disc Disease Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lumbar Degenerative Disc Disease Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lumbar Degenerative Disc Disease Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AnGes MG, Inc., AxioMed LLC, B. Braun SE, Baxter International Inc., Benvenue Medical, Inc., Biopharm GmbH, Boston Scientific Corporation, Centinel Spine, LLC, Cerapedics Inc., ChoiceSpine, DePuy Synthes by Medical Device Business Services, Inc., Globus Medical, Inc., Kolon TissueGene Inc., Kuros Biosciences, Lineage Cell Therapeutics, Inc., Medtronic plc, NLC Ventures Netherlands B.V., Notogen, Inc., Orthofix Medical Inc., RTI Surgical Holdings, Inc., Stryker Corporation, Ulrich Medical USA Inc., Veritas Health, LLC, Xtant Medical Holdings, Inc., and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Lumbar Degenerative Disc Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment
- Epidural Steroid Injections (ESIs)
- Over-the-counter (OTC) Pain Medications
  - Acetaminophen
  - Anti-inflammatories
  - Corticosteroids
  - Muscle Relaxants
  - Narcotics

Therapy Devices

Route of Administration
- Injectables
- Oral

End-Users
- Academic Research Centers
- Hospitals & Clinics
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Lumbar Degenerative Disc Disease Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lumbar Degenerative Disc Disease Market?

3. What are the technology trends and regulatory frameworks in the Lumbar Degenerative Disc Disease Market?

4. What is the market share of the leading vendors in the Lumbar Degenerative Disc Disease Market?

5. Which modes and strategic moves are suitable for entering the Lumbar Degenerative Disc Disease Market?

Product Code: MRR-D566A980152E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of lumbar degenerative disc disease
  - 5.1.1.2. Rising awareness campaigns and education about LDDD
- 5.1.2. Restraints
  - 5.1.2.1. Limited availability of reimbursement
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing R&D for introducing new LDDD treatments and diagnosis
  - 5.1.3.2. Favorable government approvals for LDDD medicine commercialization
- 5.1.4. Challenges
  - 5.1.4.1. Complexity in surgical procedures and medicine development
5.2. Market Segmentation Analysis
- 5.2.1. Treatment: Rising usage of epidural steroid injections (ESIs) for management of lumbar degenerative disc disease
- 5.2.2. End-Users: Increasing need for lumbar degenerative disc disease treatment for diagnosing, treating, and managing patients
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Lumbar Degenerative Disc Disease Market, by Treatment

6.1. Introduction
6.2. Epidural Steroid Injections (ESIs)
6.3. Over-the-counter (OTC) Pain Medications
6.4. Therapy Devices

7. Lumbar Degenerative Disc Disease Market, by Route of Administration

7.1. Introduction
7.2. Injectables
7.3. Oral

8. Lumbar Degenerative Disc Disease Market, by End-Users

8.1. Introduction
8.2. Academic Research Centers
8.3. Hospitals & Clinics
8.4. Specialty Clinics

9. Americas Lumbar Degenerative Disc Disease Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Lumbar Degenerative Disc Disease Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Lumbar Degenerative Disc Disease Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. FDA Clears ReGelTec's HYDRAFIL System for Treatment of Lumbar Degenerative Disc Disease
- 12.3.2. RIT Researchers Awarded NIH Grant to CRISPR-Enhanced Stem Cell Therapy for Lumbar Degeneration
- 12.3.3. Companion Spine Advances Global Spine Health with Strategic Acquisition of Backbone SAS
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio